Lentivirus Replication Strategy and Pathogenesis
Lentivirus Replication Strategy and Pathogenesis
批准号:
10319982
负责人:
Baek Kim
金额:
$38.55万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-01-19 至 2023-04-16
关键词:
AdoptedAnimalsAntiviral TherapyBiochemicalBiologyBrainCD4 Positive T LymphocytesCell DeathCellsChemistryDNADNA DamageDNA biosynthesisEnvironmentEnzyme KineticsEquine Infectious Anemia VirusEvolutionExhibitsFeline Immunodeficiency VirusFundingGeneticGenomicsHIVHIV-1HIV-2Hot SpotInfectionInterphase CellKineticsKnowledgeLentivirusMediatingMetabolicMicrogliaMolecular ConformationMutagenesisMutationMyelogenousMyeloid CellsPathogenesisProteinsRNA-Directed DNA PolymeraseReportingResearchRibonucleosidesSAM DomainSIVSerumTestingTherapeuticTissuesViralViral ProteinsViral Reverse TranscriptionViral reservoirVirusVirus Replicationbasecell typecomparativein vivomacrophagemutantnoveltripolyphosphate
中文摘要
项目摘要- Kim
英文摘要
Project Summary – Kim
Lentiviruses including HIV-1, HIV-2 and SIV replicate in both activated CD4+ T cells and terminally-
differentiated/non-dividing myeloid cells (e.g. macrophages). While HIV-1 rapidly replicates in activated CD4+ T
cells, HIV-1 replication in macrophages is kinetically suppressed. Our previous studies found that
macrophages harbor an extremely low dNTP concentration (20-40 nM), which kinetically restricts viral reverse
transcription, and later that the host SAMHD1 dNTPase is responsible for the limited dNTP level in
macrophages, which restricts HIV-1 replication. However, SIVsm and HIV-2 efficiently replicate even in
macrophages due to its viral protein X (Vpx) that proteosomally degrades SAMHD1 and then elevates cellular
dNTP levels in macrophages. Our long-term premise is that the extremely limited cellular dNTP pool in
nondividing myeloid cells creates unique biochemical and virological features of HIV-1 replication, which
directly influence viral replication kinetics, genomic diversity, evolution, and ultimately, pathogenesis of HIV-1.
Our previously funded research revealed that HIV-1 reverse transcriptase (RT) uniquely displays efficient DNA
synthesis capability even at the low macrophage dNTP concentrations, which enables HIV-1 to overcome the
SAMHD1-mediated limited dNTPs in macrophages. However, we found that RTs from many SIV and HIV-2
strains exhibit significantly reduced DNA synthesis capability at the low macrophage dNTP concentrations,
compared to HIV-1 RTs, supporting that HIV-2/SIV RTs did not evolve to be highly efficient, possibly because
Vpx of these viruses elevates dNTP concentrations for their RTs in macrophages. Based on these findings,
first, we hypothesize that the RT enzyme kinetics can counteract SAMHD1-mediated limited dNTP pools in
the absence of Vpx. This hypothesis predicts that RT of a SIV mutant with Vpx deletion should evolve to be
more efficient in DNA synthesis during the in vivo replication in animals in order to overcome the SAMHD1-
mediated low dNTP pools in macrophages (as HIV-1 does). Second, ancestral non-primate lentiviruses such
as FIV, BIV and EIAV also efficiently replicate in macrophages, and these ancestral lentiviruses do not encode
Vpx. Here we will test whether these non-primate lentiviruses counteract their own host SAMHD1 proteins by
proteosomally degrading SAMHD1 (as HIV-2/SIV do) or 2) evolving to harbor enzymatically efficient RTs (as
HIV-1 does). Third, we reported that HIV-1 frequently incorporates highly abundant non-canonical/mutagenic
ribonucleoside triphosphates (rNTPs) during proviral DNA synthesis, specifically in macrophages due to the
limited canonical dNTP substrates. Since the incorporation of rNTPs is the most abundant DNA damages in
cells and is also sequence-specific, we hypothesize that there are rNTP incorporation hot spots throughout
HIV-1 genomic sequences, which become mutational hot spots and ultimately enhance HIV-1 mutagenesis in
macrophages. Overall, this application aims at gaining knowledge on unique HIV-1 replication mechanism in
myeloid cells that serve as long-living viral reservoirs, ultimately developing myeloid specific anti-HIV-1 agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SAMHD1 mediated dNTP regulation and HIV in myeloid cells
-
批准号:10616679
-
项目类别:
-
资助金额:$68.89万
-
财政年份:2021
-
负责人:Baek Kim
-
依托单位:
SAMHD1 mediated dNTP regulation and HIV in myeloid cells
-
批准号:10398255
-
项目类别:
-
资助金额:$41.53万
-
财政年份:2021
-
负责人:Baek Kim
-
依托单位:
SAMHD1 mediated dNTP regulation and HIV in myeloid cells
-
批准号:10271627
-
项目类别:
-
资助金额:$38.67万
-
财政年份:2021
-
负责人:Baek Kim
-
依托单位:
Elucidating SAMHD1 in DNA Double-Strand Break Repair (Supplement)
-
批准号:10817401
-
项目类别:
-
资助金额:$5.69万
-
财政年份:2020
-
负责人:Baek Kim
-
依托单位:
SARS-CoV-2 polymerase inhibitor screening
-
批准号:10230304
-
项目类别:
-
资助金额:$20.8万
-
财政年份:2020
-
负责人:Baek Kim
-
依托单位:
Elucidating SAMHD1 in DNA Double-Strand Break Repair
-
批准号:10214575
-
项目类别:
-
资助金额:$51.06万
-
财政年份:2020
-
负责人:Baek Kim
-
依托单位:
Elucidating SAMHD1 in DNA Double-Strand Break Repair (Supplement)
-
批准号:10742588
-
项目类别:
-
资助金额:$12.41万
-
财政年份:2020
-
负责人:Baek Kim
-
依托单位:
Elucidating SAMHD1 in DNA Double-Strand Break Repair
-
批准号:10418774
-
项目类别:
-
资助金额:$50.03万
-
财政年份:2020
-
负责人:Baek Kim
-
依托单位:
Elucidating SAMHD1 in DNA Double-Strand Break Repair
-
批准号:10663248
-
项目类别:
-
资助金额:$50.02万
-
财政年份:2020
-
负责人:Baek Kim
-
依托单位:
Lentivirus Replication Strategy and Pathogenesis
-
批准号:10700321
-
项目类别:
-
资助金额:$46.17万
-
财政年份:2018
-
负责人:Baek Kim
-
依托单位:
Structural and Chemical Analysis of Highly Potent ALLINI Platform
-
批准号:9789826
-
项目类别:
-
资助金额:$38.98万
-
财政年份:2018
-
负责人:Baek Kim
-
依托单位:
Lentivirus Replication Strategy and Pathogenesis
-
批准号:10078932
-
项目类别:
-
资助金额:$38.59万
-
财政年份:2018
-
负责人:Baek Kim
-
依托单位:
Structural and Chemical Analysis of Highly Potent ALLINI Platform
-
批准号:10239022
-
项目类别:
-
资助金额:$38.98万
-
财政年份:2018
-
负责人:Baek Kim
-
依托单位:
Structural and Chemical Analysis of Highly Potent ALLINI Platform
-
批准号:10455699
-
项目类别:
-
资助金额:$38.98万
-
财政年份:2018
-
负责人:Baek Kim
-
依托单位:
HIV Reverse Transcriptase-Mediated Mutagenesis
-
批准号:8915342
-
项目类别:
-
资助金额:$4.04万
-
财政年份:2013
-
负责人:Baek Kim
-
依托单位:
HIV Reverse Transcriptase-Mediated Mutagenesis
-
批准号:8561668
-
项目类别:
-
资助金额:$59.16万
-
财政年份:2013
-
负责人:Baek Kim
-
依托单位:
HIV Reverse Transcriptase-Mediated Mutagenesis
-
批准号:9068284
-
项目类别:
-
资助金额:$57.86万
-
财政年份:2013
-
负责人:Baek Kim
-
依托单位:
HIV Reverse Transcriptase-Mediated Mutagenesis
-
批准号:8930342
-
项目类别:
-
资助金额:$0.95万
-
财政年份:2013
-
负责人:Baek Kim
-
依托单位:
HIV Reverse Transcriptase-Mediated Mutagenesis
-
批准号:8730204
-
项目类别:
-
资助金额:$57.86万
-
财政年份:2013
-
负责人:Baek Kim
-
依托单位:
SAMHD1 controls dNTP pool and HIV sensitivity to NRTIs
-
批准号:8735968
-
项目类别:
-
资助金额:$29.43万
-
财政年份:2012
-
负责人:Baek Kim
-
依托单位:
海外基金